Study of the hypoglycemic effectiveness of the drug iglarlixi (soliqua) in patients with type 2 diabetes mellitus

Урунбаева Дилором Анваровна, Омонова Зилола Тохтамурод кизи

Марказий Осиё эндокринологик журнали · 2025-yil

Annotatsiya

Relevance. Type 2 diabetes mellitus (DM2) is a chronic disease that requires gradual intensification of therapy to control glycemia. Studies show that poor control lasts up to seven years, increasing the risk of complications and health care costs. Combination medications, such as fixed-dose combinations of basal insulin and GLP-1 receptor antagonists, provide greater improvements in glycemic control and convenience (one injection per day) without increasing the risk of hypoglycemia and body weight. Purpose. To compare the efficacy and safety of a fixed combination of insulin glargine 100 U/mL with lixisenatide 50 μg/mL (iGlarLixi) compared with human insulins used in basal-bolus therapy, such as Actrapid and Insulatard Materials and methods. The study included 30 patients with type 2 diabetes: 14 of them received the drug iGlarLixy Soliqua (group 1), and 16 received a combination of actrapid and insulatard (group 2). All participants took metformin in dosages ranging from 1000 to 2500 mg per day. Research methods: . Fasting and postprandial glycemia, glycated hemoglobin (HbA1c), lipid spectrum. Results. The results showed that the first group had a significant decrease in fasting blood glucose (from 8.7±0.87 to 6.2±0.58) compared to the second group (from 8.9±0.95 to 7.4±0. 67); postprandial glycemia (13.2±1.33 to 7.9±0.67) than with the second group (from 13.25±1.34 to 9.2±0.56); In patients of the first group, the average HbA1c level after 6 months was 7.78 ± 0.80% (p < 0.05), and after 12 months - 7.20 ± 0.83% (p < 0.001). In the second group, after 6 months, HbA1c was 8.23 ± 0.80%, and after 12 months - 7.69 ± 0.76% (p < 0.05). During 12 months of therapy, 1 patient (0.71%) of the first group experienced confirmed symptomatic hypoglycemia (glycemia ≤3.9 mmol/l); there were no severe cases. In the second group, 5 patients (16.7%) noted such hypoglycemia, also without severe cases. When analyzing the lipid spectrum in patients with type 2 diabetes, hyperlipoproteinemia was revealed, with a significant increase in indicators compared to the control group. Total cholesterol (TC) levels were 34% higher (P<0.05), LDL increased by 37.5%, and triglycerides (TG) by 40.6% (P<0.01). The HDL level was lower by 60.2% (P<0.05). These results confirm data from the literature on an increase in atherogenic lipoproteins and a decrease in the antiatherogenic fraction in patients with type 2 diabetes. Conclusion. Thus, due to the ability of Soliqua to quickly achieve target levels of glycemia and glycated hemoglobin and lipid spectrum, as well as its safety and good tolerability, it can be recommended as one of the drugs of choice among hypoglycemic agents for patients with type 2 diabetes and cardiovascular diseases .

Maqola ma’lumotlari
MualliflarУрунбаева Дилором Анваровна, Омонова Зилола Тохтамурод кизи
JurnalМарказий Осиё эндокринологик журнали
NashriyotРеспублика ихтисослаштирилган эндокринология илмий-амалий тиббиёт маркази
ISSN2181-3426
Nashr sanasi2025-01-24
Jild4
Son3
TilIngliz
Ilmiy sohaTibbiyot
Indeksga qo‘shilgan2026-09-06

Maqolaning asl sahifasi

Kalit so‘zlar

сахарный диабет 2 типа, аналоги ГПП-1, Соликва СолоСтар, иГларЛикси, type 2 diabetes mellitus, GLP-1 analogues, Soliqua SoloStar, iGlarLixi, 2-tur qandli diabet, GLP-1 analoglari, Soliqua SoloStar, iGlarLixi

Ilmiy soha

Tibbiyot

Iqtibos keltirish

APAУрунбаева Дилором Анваровна, & Омонова Зилола Тохтамурод кизи (2025). STUDY OF THE HYPOGLYCEMIC EFFECTIVENESS OF THE DRUG IGLARLIXI (SOLIQUA) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. Марказий Осиё эндокринологик журнали, 4(3). https://www.tadqiqot.uz/index.php/cae/article/view/10741
GOST (OAK)Урунбаева Дилором Анваровна, Омонова Зилола Тохтамурод кизи STUDY OF THE HYPOGLYCEMIC EFFECTIVENESS OF THE DRUG IGLARLIXI (SOLIQUA) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS // Марказий Осиё эндокринологик журнали. – 2025. – T. 4, № 3.
MLAУрунбаева Дилором Анваровна, and Омонова Зилола Тохтамурод кизи. “STUDY OF THE HYPOGLYCEMIC EFFECTIVENESS OF THE DRUG IGLARLIXI (SOLIQUA) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS.” Марказий Осиё эндокринологик журнали, 4(3), 2025. https://www.tadqiqot.uz/index.php/cae/article/view/10741
ChicagoУрунбаева Дилором Анваровна, and Омонова Зилола Тохтамурод кизи. “STUDY OF THE HYPOGLYCEMIC EFFECTIVENESS OF THE DRUG IGLARLIXI (SOLIQUA) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS.” Марказий Осиё эндокринологик журнали, 4(3) (2025). https://www.tadqiqot.uz/index.php/cae/article/view/10741
HarvardУрунбаева Дилором Анваровна, and Омонова Зилола Тохтамурод кизи (2025) ‘STUDY OF THE HYPOGLYCEMIC EFFECTIVENESS OF THE DRUG IGLARLIXI (SOLIQUA) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS’, Марказий Осиё эндокринологик журнали, 4(3). https://www.tadqiqot.uz/index.php/cae/article/view/10741
BibTeX
@article{article2025,
  title = {STUDY OF THE HYPOGLYCEMIC EFFECTIVENESS OF THE DRUG IGLARLIXI (SOLIQUA) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS},
  author = {Урунбаева Дилором Анваровна and Омонова Зилола Тохтамурод кизи},
  journal = {Марказий Осиё эндокринологик журнали},
  year = {2025},
  volume = {4},
  number = {3},
  url = {https://www.tadqiqot.uz/index.php/cae/article/view/10741}
}

Boshqa maqola uchun iqtibos tayyorlash

Марказий Осиё эндокринологик журнали jurnalidan boshqa maqolalar

Марказий Осиё эндокринологик журнали — barcha maqolalar · 2025-yil arxivi

Tibbiyot sohasidagi boshqa maqolalar

Tibbiyot sohasidagi OAK jurnallari